Medical isotope production without highly enriched uranium [electronic resource] / Committee on Medical Isotope Production Without Highly Enriched Uranium, Nuclear and Radiation Studies Board, Division of Earth and Life Studies, National Research Council of the National Academies.
Publication details: Washington, D.C. : National Academies Press, c2009.Description: 1 electronic text (xviii, 202 p.) : digital, GIF, PDF, illISBN:- 9780309130394
- 0309130395
- 9780309130400 (electronic bk.)
- 0309130409 (electronic bk.)
- 9786612239243
- 6612239247
- Molybdenum -- supply & distribution -- United States
- Molybedenum -- isolation & purification -- United States
- Radioisotopes -- supply & distribution -- United States
- Technetium Compounds -- isolation & purification -- United States
- Nuclear Medicine -- standards -- United States
- Diagnostic Imaging -- United States
- Radionuclide Generators -- United States
- Quality control -- United States
- Uranium -- Isotopes
- Uranium -- Isotopes -- Therapeutic use
- Highly enriched uranium -- Isotopes -- Therapeutic use
- Molybdenum -- Isotopes -- Therapeutic use
- Technetium -- Isotopes -- Therapeutic use
- Radioisotopes -- Therapeutic use
- Nuclear medicine -- Standards -- United States
- 353.008722 22
- QD181.U7 N385 2009eb
- 2009 I-388
- WN 420
- Also issued in print.
Title from electronic title page (viewed June 1, 2009).
Includes bibliographical references.
Background and study task -- Molybdenum-99/Technetium-99m production and use -- Molybdenum-99/Technetium-99m supply -- Molybdenum-99/Technetium-99m supply reliability -- Molybdenum-99/Technetium-99m demand -- Molybdenum-99/Technetium-99m production costs -- Conversion to LEU-based production of Molybdenum-99: technical considerations -- Conversion to LEU-based production of Molybdenum-99: regulatory considerations -- Conversion to LEU-based production of Molybdenum-99: general approaches and timing -- Conversion to LEU-based production of Molybdenum-99: prospects and feasibility.
Text in GIF and PDF format.
'This book is the product of a congressionally mandated study to examine the feasibility of eliminating the use of highly enriched uranium (HEU2) in reactor fuel, reactor targets, and medical isotope production facilities. The book focuses primarily on the use of HEU for the production of the medical isotope molybdenum-99 (Mo-99), whose decay product, technetium-99m3 (Tc-99m), is used in the majority of medical diagnostic imaging procedures in the United States, and secondarily on the use of HEU for research and test reactor fuel. The supply of Mo-99 in the U.S. is likely to be unreliable until newer production sources come online. The reliability of the current supply system is an important medical isotope concern; this book concludes that achieving a cost difference of less than 10 percent in facilities that will need to convert from HEU- to LEU-based Mo-99 production is much less important than is reliability of supply.'
Also issued in print.
Sponsored by the National Academy of Sciences and the U.S. Department of Energy DE-AM01-04PI45013
Adobe Acrobat required for PDF version.
Mode of access: World Wide Web.
There are no comments on this title.
